LifeStance Health To Report Q4 And FY25 Financial Results Next Week
LifeStance Health Group, Inc. (LFST) is scheduled to release its fourth quarter and full-year 2025 financial results on February 25, 2026. The company had a strong third quarter in 2025, reporting increased revenue, a shift from net loss to net income, and a rise in adjusted EBITDA. LifeStance Health projects continued revenue growth for both Q4 2025 and the full year 2025.
LifeStance Growth Raises Questions On Scale Profitability And Shareholder Value
LifeStance Health Group is facing challenges with its growth strategy, as its expansive network of clinics and virtual services is currently resulting in subscale operations and negative returns on capital. The company's limited distribution channels compared to competitors raise concerns about its long-term profitability and shareholder value. Investors are advised to monitor whether LifeStance can improve clinician productivity and operational efficiency to convert its growth into sustainable profitability.
LifeStance to Host Fourth Quarter and Full Year 2025 Earnings Conference Call on February 25, 2026
LifeStance Health Group, Inc. (NASDAQ: LFST) will release its fourth quarter and full year 2025 earnings before the market opens on Wednesday, February 25, 2026. The company will host a live earnings conference call on the same day at 8:30 a.m. Eastern Time to discuss these results, with details provided for participation via phone or webcast.
LifeStance Health Group, Inc. (LFST) Stock Analysis: Potential 32% Upside Captures Investor Attention
LifeStance Health Group (NASDAQ: LFST) is gaining investor attention with a potential 32.16% upside, according to recent analyst ratings. The company, which provides outpatient mental health services, is valued at $2.65 billion and trades at $6.81, showing robust revenue growth of 16.30%. Despite current profitability challenges, strong analyst sentiment and a forward P/E ratio of 27.28 suggest anticipated growth, making it an appealing prospect for growth-oriented investors in the mental healthcare sector.
LifeStance to Host Fourth Quarter and Full Year 2025 Earnings Conference Call on February 25, 2026
LifeStance Health Group, Inc. (NASDAQ: LFST) will release its fourth quarter and full year 2025 earnings before market open on Wednesday, February 25, 2026. The company will host a live earnings conference call on the same day at 8:30 a.m. Eastern Time to discuss the results. Interested parties can access the call via a domestic or international dial-in number, or through a real-time audio webcast on the LifeStance Investor Relations website.
LifeStance to Host Fourth Quarter and Full Year 2025 Earnings Conference Call on February 25, 2026
LifeStance Health Group, Inc. (NASDAQ: LFST) announced it will host its fourth quarter and full year 2025 earnings conference call on February 25, 2026, at 8:30 a.m. Eastern Time. The company will release its earnings report before the market opens on the same day. LifeStance, a major provider of outpatient mental health care, will also provide a webcast of the call on its Investor Relations website.
Principal Financial Group Inc. Has $16.87 Million Stock Holdings in LifeStance Health Group, Inc. $LFST
Principal Financial Group Inc. has reduced its stake in LifeStance Health Group Inc. by 10.2%, now holding 3.07 million shares valued at $16.87 million. Insider selling has also occurred, with key executives divesting shares, though insiders still own 6.6% of the company. Despite insider sales, analyst sentiment is turning positive, with several firms upgrading ratings and a consensus "Moderate Buy" rating with an average price target of $9.00.
LifeStance to Host Fourth Quarter and Full Year 2025 Earnings Conference Call on February 25, 2026
LifeStance Health Group, Inc. (NASDAQ: LFST) announced it will release its fourth quarter and full year 2025 earnings before the market opens on Wednesday, February 25, 2026. The company will host a live conference call on the same day at 8:30 a.m. Eastern Time to discuss the results. Interested parties can access the call via phone or a real-time audio webcast on the LifeStance Investor Relations website.
LifeStance to Host Fourth Quarter and Full Year 2025 Earnings Conference Call on February 25, 2026
LifeStance Health Group, Inc. (NASDAQ: LFST) announced it will release its fourth quarter and full year 2025 earnings before the market opens on Wednesday, February 25, 2026. The company will also host a live earnings conference call on the same day at 8:30 a.m. Eastern Time to discuss the results. Interested parties can access the call via phone or a real-time audio webcast on the LifeStance Investor Relations website.
LifeStance Health Group, Inc. to Announce Q4 and Full Year 2025 Earnings on February 25, 2026
LifeStance Health Group, Inc. (LFST) will release its Q4 and full-year 2025 earnings on February 25, 2026, before market open, followed by a conference call at 8:30 a.m. Eastern Time. The company, a significant provider of outpatient mental health care across 33 states, will discuss its financial results and operations. The article also provides details on recent insider trading activity, hedge fund movements, and analyst ratings for LFST.
LifeStance Health Group (NASDAQ:LFST) Upgraded to "Buy" at Wall Street Zen
LifeStance Health Group (NASDAQ:LFST) was upgraded to a "buy" rating by Wall Street Zen on Sunday, February 8, 2026, joining several other firms that have issued positive ratings. The company recently reported Q4 results with revenue of $363.8 million, up 16.3% year-over-year, and EPS of $0.02, beating estimates, though it remains broadly unprofitable. Insider selling for the quarter totaled approximately $2.26 million, while institutional ownership stands high at 85.5%.
LifeStance Health Group, Inc. (LFST): Analyst Consensus Points To 23.8% Upside Potential
LifeStance Health Group, Inc. (LFST) is attracting investor interest with its focus on expanding mental health services and a significant upside potential of 23.8% according to analyst consensus. The company, headquartered in Scottsdale, Arizona, has a market cap of $2.79 billion and reported strong revenue growth of 16.3%, though it currently has a negative EPS and ROE. LFST stock is trading above its 50-day and 200-day moving averages, and with a low RSI, could present a buying opportunity despite not offering a dividend.
Should Analyst Revisions and 16% Revenue Growth Require Action From LifeStance Health Group (LFST) Investors?
LifeStance Health Group (LFST) has seen updated analyst views and reported strong revenue growth of 16.34% as of September 30, 2025. While analysts have issued modestly higher price targets, the company's valuation faces scrutiny due to a high price-to-sales ratio and ongoing losses, despite positive developments like the Calm Health partnership and improving earnings trends. Investors are advised to consider execution risks and valuation carefully.
LifeStance Health Group, Inc. $LFST Shares Sold by Summit Partners L P
Summit Partners L P significantly reduced its stake in LifeStance Health Group (NASDAQ:LFST) by 20.1% in Q3, selling over 8.4 million shares, though LFST remains its second-largest holding. Meanwhile, other institutional investors have adjusted their positions, and company insiders have sold 327,326 shares over the last three months. Despite insider selling, LifeStance reported strong Q3 earnings, beating EPS and revenue estimates, while analysts currently hold a "Moderate Buy" consensus rating with an average $9 price target.
LifeStance Health Group (NASDAQ:LFST) Cut to Hold at Wall Street Zen
Wall Street Zen has downgraded LifeStance Health Group (NASDAQ:LFST) from a "buy" to a "hold" rating, though MarketBeat's consensus remains a "Moderate Buy" with an average target price of $8.83. The company, which opened at $7.07 with a $2.75 billion market cap, recently beat revenue and EPS estimates, but analysts forecast a negative EPS of -0.18 for the current fiscal year. Insider sales totaling approximately $2.26 million occurred in the last three months, while institutional investors, including Vanguard, increased their holdings.
AustralianSuper Pty Ltd Acquires New Stake in LifeStance Health Group, Inc. $LFST
AustralianSuper Pty Ltd has acquired a new stake in LifeStance Health Group, Inc. (NASDAQ:LFST), purchasing over 3.1 million shares valued at approximately $17.06 million, representing 0.80% ownership. The company's stock shows a "Moderate Buy" consensus from analysts with a target price of $8.83, despite recent insider selling totaling over $2.25 million. LifeStance Health Group reported strong revenue growth of 16.3% and beat EPS estimates in its last quarter.
LifeStance Health (LFST) Accelerates Growth with AI-Enabled Operations and Clinician Expansion
LifeStance Health is focusing on leveraging AI to streamline its operational processes and enhance the clinician experience. The company aims to expand its clinician base by 10-15% annually to meet the growing demand for mental healthcare services. These strategic initiatives are expected to drive significant growth and improve profitability for LifeStance Health.
Is K-pop music bad for your mental health? The answer might surprise you
K-pop's impact on mental health is complex, offering both benefits and risks. For many, it provides joy, belonging, and healing, helping multicultural individuals reconnect with their identity and offering emotional processing through its music and community. However, the industry's high pressure for perfection can lead to unrealistic expectations, body dissatisfaction, and emotional exhaustion among both idols and fans, highlighting the need for mindful engagement and healthy fandom.
LifeStance Health Group, Inc. (LFST) Investor Outlook: Analyzing a 21.6% Potential Upside with Strong Buy Ratings
LifeStance Health Group (LFST) demonstrates a strong potential upside of 21.6%, backed by favorable analyst ratings and significant revenue growth in the burgeoning mental health sector. Despite current profitability challenges, the company's substantial free cash flow and strategic market positioning suggest long-term value creation. Investors are encouraged to consider the company's growth trajectory and positive sentiment within their investment strategies.
Insurer-Supported Access To Care Could Be A Game Changer For LifeStance Health Group (LFST)
Analysts are optimistic about LifeStance Health Group (LFST) due to strengthening business momentum and supportive payer policies expanding in-network access to behavioral healthcare. The company's investment narrative is centered on moving towards sustained profitability by riding the growing demand for mental health services, reinforced by payer alignment and recent partnerships. While the stock has seen a strong run, valuation concerns and execution risks remain factors for investors to consider.
Analysts turn more bullish on LifeStance Health Group (LFST) after dual price target hikes
This article from MSN is incomplete and contains no meaningful content. Therefore, a summary cannot be provided.
LifeStance Health Group (NASDAQ:LFST) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen has upgraded LifeStance Health Group (NASDAQ:LFST) from "hold" to "buy," aligning with other brokers that have raised price targets for the company. The mental health services provider exceeded quarterly earnings and revenue expectations, though it still has a negative net margin. Despite significant insider selling totaling $2.26 million, institutional investors hold a substantial 85.5% stake in the company.
Analysts Turn More Bullish on LifeStance Health Group (LFST) After Dual Price Target Hikes
KeyBanc and Canaccord analysts have increased their price targets for LifeStance Health Group (LFST), signaling a more bullish outlook for the mental health services provider. KeyBanc raised its target from $6.50 to $8.50, maintaining an "Overweight" rating, while Canaccord increased its target from $8.00 to $9.00, keeping a "Buy" rating. Both firms cite positive momentum, stabilization in the HCIT shares, and favorable payer policies as factors contributing to LFST's potential.
LifeStance (LFST) Extends 4-Day Run on Strong Earnings
LifeStance (LFST) is experiencing a four-day winning streak, driven by positive reactions to its 최근 earnings report. The stock has seen significant price appreciation following the strong financial results. This extended run highlights investor confidence in the company's performance.
LifeStance (LFST) Extends 4-Day Run on Strong Earnings
LifeStance Health Group (LFST) has seen its stock price increase for four consecutive days, a positive trend influenced by its recent strong earnings report. The mental healthcare services provider likely benefited from exceeding analyst expectations or providing optimistic forward guidance, leading to increased investor confidence and buying activity.
LifeStance Health Group, Inc. (NASDAQ:LFST) Given Average Rating of "Moderate Buy" by Brokerages
LifeStance Health Group (NASDAQ:LFST) has received an average rating of "Moderate Buy" from nine analysts, with an average 12-month target price of $8.83. Several brokers recently raised their price targets to $10, and Barclays initiated coverage with an "overweight" rating. Despite beating earnings expectations in the last quarter, the company remains unprofitable, and insiders have recently sold a significant number of shares.
LifeStance Health Group (LFST) Stock Analysis: Exploring a 20% Potential Upside for Investors
LifeStance Health Group (LFST) is a prominent healthcare provider in the mental health sector, showing strong revenue growth of 16.30% with a market cap of $2.77 billion. Analysts are largely optimistic about LFST, projecting a potential upside of 20.16%, despite the company currently not reporting positive net income. The company's robust free cash flow of $123.6 million and hybrid care model position it as an intriguing investment opportunity in a growing market.
LifeStance Health Group (NASDAQ:LFST) Director Robert Bessler Sells 119,942 Shares
LifeStance Health Group Director Robert Bessler recently sold 119,942 shares of the company's stock for over $844,000, reducing his stake by 8.34%. This sale is part of multiple transactions in December totaling around 220,086 shares sold for approximately $1.55 million. The company (NASDAQ:LFST) is trading near $7.06 with a market cap of $2.75 billion, receiving a "Moderate Buy" consensus rating from analysts despite remaining slightly unprofitable.
LifeStance Health Group (NASDAQ:LFST) Director Sells $11,975.04 in Stock
LifeStance Health Group (NASDAQ:LFST) Director Robert Bessler sold 1,701 shares of the company's stock for a total of $11,975.04 on December 22nd, reducing his position by 0.13%. This sale is part of a series of transactions by Bessler from December 12th to 22nd, totaling approximately 220,086 shares for about $1.55 million, though he still retains 1,318,133 shares valued at around $9.28 million. LifeStance Health Group's stock traded at $7.06, with a market capitalization of $2.75 billion, and the company recently surpassed quarterly EPS and revenue estimates while maintaining a "Moderate Buy" consensus rating from analysts with an $8.83 target.
LifeStance Health director Bessler sells $856k in shares
Robert Bessler, a director at LifeStance Health Group, Inc. (NASDAQ:LFST), sold a total of $856,366 worth of common stock across several transactions on December 19 and 22, 2025. These sales were executed at a price of $7.04 per share, with shares sold both directly and indirectly through LLCs. Following these transactions, Bessler still indirectly holds over 2.7 million shares in the company.
LifeStance Health director Bessler sells $856k in shares By Investing.com
Robert Bessler, a director at LifeStance Health Group, Inc. (NASDAQ:LFST), sold a total of $856,366 worth of common stock in multiple transactions on December 19 and December 22, 2025, at an average price of $7.04 per share. Following these sales, Bessler still indirectly holds a substantial number of shares through various entities and directly. The company recently reported mixed Q3 2025 earnings with revenue surpassing forecasts but EPS falling short, leading to a surge in pre-market trading despite the mixed results.
2026 Medical Utilization Forecasts Support BTIG's Bullish View on LifeStance (LFST)
BTIG analyst David Larsen reiterated a bullish stance on LifeStance Health Group (LFST), raising the price target from $9 to $10, forecasting a 42% upside potential for investors. This positive outlook is driven by anticipated strong medical utilization trends in 2026, stemming from a favorable labor market and increased demand for medical oncology, mental health services, and specialty medications. Currently, all seven analysts covering LFST have issued Buy ratings, with a consensus 1-year average price target of $9, suggesting a 27.7% upside.
Insider Sell: Ann Varanakis Sells 50,000 Shares of LifeStance He
Ann Varanakis, Chief People Officer at LifeStance Health Group Inc (LFST), sold 50,000 shares of the company on December 17, 2025. This transaction increased her total shares owned to 315,610. The stock, currently trading at $6.9, is considered modestly undervalued with a GuruFocus Value of $8.14.
Have Insiders Sold LifeStance Health Group Shares Recently?
An independent director at LifeStance Health Group (NASDAQ:LFST) recently sold approximately US$645k worth of shares, representing a 3.1% reduction in their holding. This was the largest insider sale in the past year, and while the sale occurred near the current share price, it indicates more selling than buying activity from insiders over the last year. Despite insiders owning a significant 7.8% of the company, the analysis suggests caution regarding the stock due to the recent selling trend.
Robert Bessler Sells 6,442 Shares of LifeStance Health Group (NASDAQ:LFST) Stock
Director Robert Bessler sold 6,442 shares of LifeStance Health Group (NASDAQ:LFST) stock on December 18th for $7.00 per share, totaling $45,094. This sale, along with previous transactions on December 12th and 15th, reduced his ownership by 0.46% to 1,378,954 shares. LifeStance Health Group's stock traded up $0.11 to $7.05, and the company recently beat EPS estimates with a 16.3% rise in revenue year-over-year, leading to a "Moderate Buy" consensus rating from analysts.
Ann Varanakis Sells 50,000 Shares of LifeStance Health Group (NASDAQ:LFST) Stock
Ann Varanakis, an insider at LifeStance Health Group (NASDAQ:LFST), sold 50,000 shares of the company's stock on December 17th, reducing her ownership by 13.68%. The transaction was valued at $345,000. LifeStance recently reported strong quarterly earnings, beating analyst expectations for EPS and showing significant revenue growth.
Lifestance Health Group Insider Sold Shares Worth $345,000, According to a Recent SEC Filing
An insider at LifeStance Health Group (LFST) recently sold $345,000 worth of shares, as detailed in a SEC filing. This transaction was reported on December 19, 2025. The company specializes in virtual and in-person mental healthcare services for various age groups and conditions.
Have Insiders Sold LifeStance Health Group Shares Recently?
An independent director at LifeStance Health Group recently sold shares worth US$645k, reducing their holding by 3.1%. While this was the largest insider sale in the last year, it occurred at a price close to the current share price, making it less concerning than a sale at a lower price. Insider ownership remains significant at 7.8% of the company, but overall insider transactions from the past year indicate more selling than buying.
Dir Bessler Sells 92,001 ($644.8K) Of Lifestance Health Group Inc [LFST]
Robert Bessler, a Director at Lifestance Health Group Inc. (LFST), filed a Form 4 detailing the sale of 92,001 shares between December 12-15, 2025. The shares were sold at $7.01 each, totaling $644,807, and were executed as part of a prearranged trading plan (10b5-1). Following the transaction, Bessler's total holdings stand at 2,962,761 shares.
Insider Selling: LifeStance Health Group (NASDAQ:LFST) Director Sells 79,630 Shares of Stock
Robert Bessler, a Director at LifeStance Health Group (NASDAQ:LFST), sold a total of 79,630 shares at $7.01 and an additional 12,371 shares at $7.00 in mid-December, reducing his stake by 5.45%. Despite the sales, Bessler still holds over 1.38 million shares valued at approximately $9.69 million. The company recently reported better-than-expected quarterly EPS of $0.02 and revenue of $363.8 million, though it faces a negative net margin and projected negative EPS for the year.
Insider Selling: LifeStance Health Group (NASDAQ:LFST) Director Sells 12,371 Shares of Stock
LifeStance Health Group (NASDAQ:LFST) Director Robert Bessler sold 12,371 shares of the company's stock on December 15th for $86,597, reducing his stake by 0.89%. This follows a previous sale of 79,630 shares on December 12th. Despite recent insider selling, analysts maintain a "Moderate Buy" rating for LFST with an average price target of $8.83, following better-than-expected Q3 earnings where the company reported $0.02 EPS and 16.3% YoY revenue growth.
Squarepoint Ops LLC Buys 981,349 Shares of LifeStance Health Group, Inc. $LFST
Squarepoint Ops LLC significantly increased its stake in LifeStance Health Group, acquiring an additional 981,349 shares, bringing its total to over 1.3 million shares valued at approximately $7.03 million. This comes as analyst sentiment for LifeStance has generally turned positive, with several firms issuing "outperform" or "buy" ratings and an average price target of $9.00. The company recently surpassed quarterly earnings and revenue estimates, though it still reported a slight negative net margin.
BTIG Research Issues Positive Forecast for LifeStance Health Group (NASDAQ:LFST) Stock Price
BTIG Research raised its target price for LifeStance Health Group (NASDAQ:LFST) to $10 from $9, maintaining a "buy" rating and implying a 47.9% upside. While LifeStance beat Q3 earnings estimates with $0.02 EPS and $363.8 million revenue, it remains slightly unprofitable, with analysts projecting -$0.18 EPS for the fiscal year. Institutional investors hold a significant portion of the company's shares, despite recent insider selling by Lisa K. Miller.
BTIG Maintains LifeStance Health Group (LFST) Buy Recommendation
BTIG has reiterated its Buy recommendation for LifeStance Health Group (LFST), with an average one-year price target of $8.74, suggesting a 29.33% upside. Institutional ownership shows a bullish outlook, with increases in total shares owned and a put/call ratio of 0.67.
LifeStance Health Group (NASDAQ:LFST) Upgraded at Barclays
Barclays upgraded LifeStance Health Group (NASDAQ:LFST) to a "strong-buy" rating, with an average analyst price target of $8.86. The company reported better-than-expected quarterly EPS of $0.02 and strong revenue growth of 16.3% year-over-year, reaching $363.8 million. Insider Lisa K. Miller recently sold 57,240 shares, though institutional investors like Vanguard and Barclays have increased their stakes, holding approximately 85.5% of the stock.
Brown Advisory Inc. Sells 611,977 Shares of LifeStance Health Group, Inc. $LFST
Brown Advisory Inc. reduced its stake in LifeStance Health Group (NASDAQ:LFST) by 10.5% in Q2, selling 611,977 shares and now owning 5,210,638 shares valued at $26.94 million. Analysts maintain a "Moderate Buy" consensus rating with an average target price of $9.00. Insider Lisa K. Miller also sold 57,240 shares, reducing her ownership by 17.97%.
LifeStance to Pay $3 Million in Revised Web Tracking Settlement
LifeStance Health Group Inc. has agreed to pay over $3 million to settle a class action lawsuit regarding the online tracking of mental health patients. The revised settlement, submitted for preliminary approval, includes a reduced attorneys' fee request of no more than $756,968, down from at least $1.05 million, after a federal judge raised concerns about the initial request.
LifeStance Health Group, Inc. $LFST Shares Acquired by Loomis Sayles & Co. L P
Loomis Sayles & Co. L P increased its stake in LifeStance Health Group (NASDAQ:LFST) by 4.5% in Q2, bringing their total to over 2.3 million shares valued at $12.11 million. Institutional investors now collectively own about 85.5% of the company's stock. Analysts hold a "Moderate Buy" consensus with an average target price of $9.00, while the company recently beat quarterly earnings estimates and saw an insider share sale.
Geode Capital Management LLC Has $17.40 Million Stock Position in LifeStance Health Group, Inc. $LFST
Geode Capital Management LLC reduced its stake in LifeStance Health Group, Inc. (NASDAQ:LFST) by 4.0% in the second quarter, now holding 3,365,403 shares valued at $17.40 million. Institutional investors collectively own 85.50% of the company's stock, while insiders hold about 6.60%, with one insider recently selling a significant portion of her shares. Despite beating Q3 earnings and revenue estimates, the company continues to show a negative PE ratio and net margin, and analysts have a "Moderate Buy" rating with an average target price of $9.00.
Have Insiders Sold LifeStance Health Group Shares Recently?
An Executive Vice President at LifeStance Health Group recently sold a significant amount of shares, reducing their holding by 18%. While there was a notable insider purchase in the last year, it was at a lower price point and overall insider selling has outweighed buying. Despite insiders owning a substantial portion of the company, their recent transaction activity raises concerns.
